Men's Health Trials

Return to Full Search

Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial

IRB/UVa Tracking #: 16604

Principal Investigator: Timothy Showalter

Contact: Amy Smith

Tel: +1 434-243-1619


Study Description

UVA Health System, Department of Radiation Oncology seeks men, ages 18 and older with prostate cancer for a research study. Currently, at UVA, the standard radiation therapy course length for this type of cancer is around 7 ½ -8 weeks. The purpose of this study is to test the safety of a shorter course of radiation therapy at progressively lower dose levels and shorter lengths of treatment (hypofractionated) with patients who have had their prostate removed. We would like to find out what effects (good and bad) the shorter course has on prostate cancer patients and their cancer. The study will test whether the hypofractionated course works better than the standard therapy course. Participation in this study will require up to 5 study visits per week for up to 5 weeks. Follow-up visits will be conducted at 1 month, 3, 6, 12, and 24 months after completion of radiation therapy. Contact information: Department of Radiation Oncology, 434-243-7231 IRB-HSR# 16604 Principal Investigator: Timothy Showalter, MD